<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33757953</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>23</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol.</ArticleTitle><Pagination><StartPage>e044996</StartPage><MedlinePgn>e044996</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e044996</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2020-044996</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Motor neuron disease (MND) is a rapidly progressive and fatal neurodegenerative disorder with limited treatment options. The Motor Neuron Disease Systematic Multi-Arm Randomised Adaptive Trial (MND-SMART) is a multisite UK trial seeking to address the paucity in effective disease-modifying drugs for people with MND (pwMND). Historically, neurological trials have been plagued by suboptimal recruitment and high rates of attrition. Failure to recruit and/or retain participants can cause insufficiently representative samples, terminated trials or invalid conclusions. This study investigates patient-specific factors affecting recruitment and retention of pwMND to MND-SMART. Improved understanding of these factors may improve trial protocol design, optimise recruitment and retention.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">PwMND on the Scottish MND Register, Clinical Audit Research and Evaluation of MND (CARE-MND), will be invited to participate in a prospective observational cohort study that investigates factors affecting trial participation and attrition. We hypothesise that patient-specific factors will significantly affect trial recruitment and retention. Participants will complete the Hospital Anxiety and Depression Scale, 9-Item Patient Health Questionnaire and State-Trait Anxiety Inventory-Form Y to evaluate neuropsychiatric symptoms, the ALS-Specific Quality of Life Questionnaire-Brief Form and Centre for Disease Control and Prevention-Health-Related Quality of Life for quality of life and a novel study-specific questionnaire on Attitudes towards Clinical Trial Participation (ACT-Q). Clinical data on phenotype, cognition (Edinburgh Cognitive and Behavioural ALS Screen) and physical functioning (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised) will also be collated. Caregivers will complete the Brief Dimensional Apathy Scale. After 12 months, a data request to MND-SMART will evaluate recruitment and retention. Descriptive statistics will summarise and compare assessments and participants reaching impairment thresholds. Variable groupings: attitudes, quality of life, cognition, behaviour, physical functioning, neuropsychiatric and phenotype. Univariate and multivariable logistic regression will explore association with participation/withdrawal in MND-SMART; presented as ORs and 95% CIs.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">Ethical approval was provided by the West of Scotland Research Ethics Committee 3 (20/WS/0067) on 12 May 2020. The results of this study will be published in a peer-reviewed journal, presented at academic conferences and disseminated to participants and the public.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beswick</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9843-0778</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glasmacher</LastName><ForeName>Stella A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-1165-9153</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dakin</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neurosciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK suvankar.pal@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anne Rowling Regenerative Neurology Clinic, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The National Creutzfeldt-Jakob Disease Research and Surveillance Unit, Western General Hospital, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012606" MajorTopicYN="N" Type="Geographic">Scotland</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">motor neurone disease</Keyword><Keyword MajorTopicYN="N">neurology</Keyword></KeywordList><CoiStatement>Competing interests: Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33757953</ArticleId><ArticleId IdType="pmc">PMC7993162</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2020-044996</ArticleId><ArticleId IdType="pii">bmjopen-2020-044996</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leighton DJ, Newton J, Stephenson LJ, et al. . Changing epidemiology of motor neurone disease in Scotland. J Neurol 2019;266:817&#x2013;25. 10.1007/s00415-019-09190-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09190-7</ArticleId><ArticleId IdType="pubmed">30805795</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, et al. . Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2020;21:509&#x2013;18. 10.1080/21678421.2020.1771734</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al. . Revised airlie house consensus guidelines for design and implementation of ALS clinical trials. Neurology 2019;92:e1610&#x2013;23. 10.1212/WNL.0000000000007242</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Gul RB, Ali PA. Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs 2010;19:227&#x2013;33. 10.1111/j.1365-2702.2009.03041.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2702.2009.03041.x</ArticleId><ArticleId IdType="pubmed">20500260</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Yerramilli-Rao P, Szymonifka J, et al. . Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology 2013;81:1350&#x2013;5. 10.1212/WNL.0b013e3182a823e0</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a823e0</ArticleId><ArticleId IdType="pmc">PMC3806927</ArticleId><ArticleId IdType="pubmed">24005339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Pastula DM, Welsh E, et al. . Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler 2008;9:257&#x2013;65. 10.1080/17482960802195913</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802195913</ArticleId><ArticleId IdType="pubmed">18608092</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Westeneng H-J, Nikolakopoulos S, et al. . Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology 2019;92:e451&#x2013;60. 10.1212/WNL.0000000000006855</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006855</ArticleId><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. BMJ 2006;332:969&#x2013;71. 10.1136/bmj.332.7547.969</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.332.7547.969</ArticleId><ArticleId IdType="pmc">PMC1444839</ArticleId><ArticleId IdType="pubmed">16627519</ArticleId></ArticleIdList></Reference><Reference><Citation>Min J-H, Hong Y-H, Sung J-J, et al. . Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci 2012;27:200&#x2013;6. 10.3346/jkms.2012.27.2.200</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2012.27.2.200</ArticleId><ArticleId IdType="pmc">PMC3271295</ArticleId><ArticleId IdType="pubmed">22323869</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Pupillo E, Bonito V, et al. . Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:397&#x2013;405. 10.3109/21678421.2013.764568</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.764568</ArticleId><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Polit D, Hungler B. Essentials of nursing research: principles and methods. Philadelphia: Lippincott Williams &amp;Williams, 2001.</Citation></Reference><Reference><Citation>Drew A, Baird G, Baron-Cohen S, et al. . A pilot randomised control trial of a parent training intervention for pre-school children with autism. Eur Child Adolesc Psychiatry 2002;11:266&#x2013;72. 10.1007/s00787-002-0299-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00787-002-0299-6</ArticleId><ArticleId IdType="pubmed">12541005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross D, Fogg L. Clinical trials in the 21st century: the case for participant-centered research. Res Nurs Health 2001;24:530&#x2013;9. 10.1002/nur.10010</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nur.10010</ArticleId><ArticleId IdType="pubmed">11746081</ArticleId></ArticleIdList></Reference><Reference><Citation>Scale ALSFR. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I&#x2010;II study. GrouArch Neurol 1996;53:141&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8639063</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaki T, Wason JMS. Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study. BMC Cardiovasc Disord 2018;18:215. 10.1186/s12872-018-0956-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-018-0956-4</ArticleId><ArticleId IdType="pmc">PMC6260683</ArticleId><ArticleId IdType="pubmed">30482176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydes MR, Parmar MKB, James ND, et al. . Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009;10:39. 10.1186/1745-6215-10-39</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-10-39</ArticleId><ArticleId IdType="pmc">PMC2704188</ArticleId><ArticleId IdType="pubmed">19519885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Ann Oncol 2000;11:939&#x2013;46. 10.1023/A:1008342222205</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1008342222205</ArticleId><ArticleId IdType="pubmed">11038029</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman LM, et al. . Fundamentals of clinical trials. Vol 4. Springer, 2010.</Citation></Reference><Reference><Citation>Cooley ME, Sarna L, Brown JK, et al. . Challenges of recruitment and retention in multisite clinical research. Cancer Nurs 2003;26:376&#x2013;86. 10.1097/00002820-200310000-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002820-200310000-00006</ArticleId><ArticleId IdType="pubmed">14710799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunninghake DB, Darby CA, Probstfield JL. Recruitment experience in clinical trials: literature summary and annotated bibliography. Control Clin Trials 1987;8:6&#x2013;30. 10.1016/0197-2456(87)90004-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(87)90004-3</ArticleId><ArticleId IdType="pubmed">3326716</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen SM, Mirza MR, Holm S, et al. . Attitudes towards clinical research amongst participants and nonparticipants. J Intern Med 2002;251:156&#x2013;68. 10.1046/j.1365-2796.2002.00949.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2796.2002.00949.x</ArticleId><ArticleId IdType="pubmed">11905591</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern J. The Scottish motor neuron disease register: a prospective study of adult onset motor neuron disease in Scotland. methodology, demography and clinical features of incident cases in 1989. J Neurol Neurosurg Psychiatry 1992;55:536&#x2013;41. 10.1136/jnnp.55.7.536</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.55.7.536</ArticleId><ArticleId IdType="pmc">PMC489161</ArticleId><ArticleId IdType="pubmed">1640227</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighton D, Newton J, Colville S, et al. . Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:242&#x2013;50. 10.1080/21678421.2019.1582673</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582673</ArticleId><ArticleId IdType="pubmed">30889975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P, Abrahams S, Masi D, et al. . Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol 2007;14:993&#x2013;1001. 10.1111/j.1468-1331.2007.01843.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01843.x</ArticleId><ArticleId IdType="pubmed">17718691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessel KA, Vogel MME, Kessel C, et al. . Cancer clinical trials&#x2013;Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC). Clin Transl Radiat Oncol 2018;13:44&#x2013;9. 10.1016/j.ctro.2018.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctro.2018.10.001</ArticleId><ArticleId IdType="pmc">PMC6192009</ArticleId><ArticleId IdType="pubmed">30345398</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. When to use the B onferroni correction. Ophthalmic Physiol Opt 2014;34:502&#x2013;8. 10.1111/opo.12131</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/opo.12131</ArticleId><ArticleId IdType="pubmed">24697967</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford JR, Henry JD, Crombie C, et al. . Normative data for the HADS from a large non-clinical sample. Br J Clin Psychol 2001;40:429&#x2013;34. 10.1348/014466501163904</Citation><ArticleIdList><ArticleId IdType="doi">10.1348/014466501163904</ArticleId><ArticleId IdType="pubmed">11760618</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons CJ, Mills RJ, Thornton EW, et al. . Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health Qual Life Outcomes 2011;9:82. 10.1186/1477-7525-9-82</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-9-82</ArticleId><ArticleId IdType="pmc">PMC3192662</ArticleId><ArticleId IdType="pubmed">21955749</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielberger CD. State&#x2010;Trait anxiety inventory. Corsini Encyclopedia Psychol 2010.</Citation></Reference><Reference><Citation>Sjonnesen K, Berzins S, Fiest KM, et al. . Evaluation of the 9-item patient health questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. Postgrad Med 2012;124:69&#x2013;77. 10.3810/pgm.2012.09.2595</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/pgm.2012.09.2595</ArticleId><ArticleId IdType="pubmed">23095427</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. primary care evaluation of mental disorders. patient health questionnaire. JAMA 1999;282:1737&#x2013;44. 10.1001/jama.282.18.1737</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.282.18.1737</ArticleId><ArticleId IdType="pubmed">10568646</ArticleId></ArticleIdList></Reference><Reference><Citation>Felgoise SH, Feinberg R, Stephens HE, et al. . Amyotrophic lateral sclerosis-specific quality of life-short form (ALSSQOL-SF): a brief, reliable, and valid version of the ALSSQOL-R. Muscle Nerve 2018;58:646&#x2013;54. 10.1002/mus.26203</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26203</ArticleId><ArticleId IdType="pubmed">30028537</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy CH, Moriarty DG, Zack MM, et al. . Measuring health-related quality of life for public health surveillance. Public Health Rep 1994;109:665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1403555</ArticleId><ArticleId IdType="pubmed">7938388</ArticleId></ArticleIdList></Reference><Reference><Citation>Radakovic R, Stephenson L, Colville S, et al. . Multidimensional apathy in ALS: validation of the dimensional apathy scale. J Neurol Neurosurg Psychiatry 2016;87:663&#x2013;9. 10.1136/jnnp-2015-310772</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310772</ArticleId><ArticleId IdType="pubmed">26203157</ArticleId></ArticleIdList></Reference><Reference><Citation>Radakovic R, McGrory S, Chandran S, et al. . The brief dimensional apathy scale: a short clinical assessment of apathy. Clin Neuropsychol 2020;34:423&#x2013;35. 10.1080/13854046.2019.1621382</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854046.2019.1621382</ArticleId><ArticleId IdType="pubmed">31154933</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, et al. . Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:9&#x2013;14. 10.3109/21678421.2013.805784</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>